PTPRC and acute lymphoblastic leukemia: We demonstrate that our shape-based analysis enables us to predict relapse in ALL patients with very high accuracy (see Fig 1) and we independently confirm the known biomarkers CD10, CD20, CD38 and/or CD45 as most relevant for relapse (R) versus non-relapse (NR) classification.